Study profile.

<p>⁺Patients were excluded, because of infection with <i>S</i>. <i>haematobium</i>. *Participants not terminating the study are summarized as lost to follow up (n = 16).</p

Antibody titers against the three vaccine strains at baseline (day 0), day 28 and day 84.

<p>Red lines indicate the mean of all volunteers of the antihelminthic treated group (AT) and blue lines indicate the mean of all participants of the placebo group. Dashed lines indicate antibody titers of each participant.</p

Baseline characteristics and helminth infection at day -28.

<p>Baseline characteristics and helminth infection at day -28.</p

GMT of vaccine strain specific antibodies.

<p>GMT of vaccine strain specific antibodies.</p

Vaccine-specific IgG ASCs at day 0 and day 84, in antihelminthic treated (AT) and placebo group.

<p>Red and blue represent antihelminthic treated (AT) and control group.</p

Differences of HI titers between the respective visits (day 28, day 84) and day 0 (baseline).

<p>Red and blue colors represent the pre-treated (AT) and control group.</p

Vaccine specific IgA at day 0, day 28 and day 84 in antihelminthic treated (AT) (red) and placebo group (blue).

<p>Vaccine specific IgA at day 0, day 28 and day 84 in antihelminthic treated (AT) (red) and placebo group (blue).</p

Distribution of the worm burden in the two groups at day 0 and day 84.

<p>Distribution of the worm burden in the two groups at day 0 and day 84.</p

Participant flow diagram.

<p>Randomisation and flow of participants over a period of 6 months for adults (cohorts 1 to 5), adolescents (cohort 6; 13–17 years), and children (cohort 7; 6–12 years). Similar dose groups are matched with shading (light grey, 3 × 10⁶ PFU; dark grey, 2 × 10⁷ PFU). GP, glycoprotein; ELISA, enzyme-linked immunosorbent assay; PFU, plaque-forming units; rVSV, recombinant vesicular stomatitis virus.</p

Geometric mean titres of ZEBOV antibodies in adults by baseline antibody status measured by whole-virion ELISA.

<p>Geometric mean titres of ZEBOV antibodies in adults by baseline antibody status measured by whole-virion ELISA.</p